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Background: Blinded food challenges are considered the current gold standard for the 
diagnosis of food allergies. We used data from a pan- European multicenter project to 
assess differences between study centers, aiming to identify the impact of subjective 
aspects for the interpretation of oral food challenges.
Methods: Nine study centers of the EuroPrevall birth cohort study about food allergy 
recruited 12 049 newborns and followed them for up to 30 months in regular inter-
vals. Intensive training was conducted and every center visited to ensure similar 
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1  | INTRODUCTION
Food allergy (FA) appears in diverse clinical patterns, typically involv-
ing the cutaneous, gastrointestinal, respiratory and cardiovascular 
systems.1 Besides observable clinical signs, many patients and parents 
also report subjective symptoms. Infants may present with being un-
comfortable or crying and preschool children may present with food 
refusal, unable to adequately express specific symptoms. A causal link 
to a trigger food is usually suspected when signs or symptoms occur 
within 2 hours of ingestion but delayed appearance is sometimes ob-
served, for example worsening of eczema and gastrointestinal symp-
toms. The heterogeneity of FA impedes the development of a simple, 
comprehensive diagnostic workup.2-5
Clinical evaluation of FA is usually set in motion based on a sug-
gestive medical history, sometimes complemented through a pro-
spective dietician- supervised elimination diet. When the diagnosis 
is based only on self- reported symptoms or objective signs, a high 
number of healthy individuals are labeled food allergic.6,7 Objective 
assessment of sensitization (eg, skin prick test, allergen- specific immu-
noglobulin E) is considered to be the first step toward a more objective 
case definition,1,8 but only challenge testing can verify the etiologic 
role of a suspected food.9 Current guidelines describe double- blind, 
placebo- controlled food challenges (DBPCFC) as the highest diagnos-
tic standard.4,8,10
Variability may be introduced at the level of an individual physician’s 
appraisal of signs and symptoms during food challenges, especially as 
those reported by food- allergic patients are expected to overlap with 
those of healthy individuals to a certain degree. A permissive decision 
point should be chosen to miss only a small number of possible food 
allergies, including mild types, but this may result in falsely labeling 
healthy individuals as food allergic, leading to unnecessary restriction 
of nutrition and to faulty self- perception of FA status. This may be 
an appropriate trade- off in clinical settings to secure the diagnosis of 
potentially life- threatening FA, but in research, observational and in-
terventional, choosing a restrictive decision point based on more ob-
jectively measurable signs or symptoms would reduce the number of 
false positives and would strengthen comparability of data between 
study physicians (Figure 1).
The impact of personal experience and subjective appraisal of the 
clinical appearance on the diagnostic interpretation of blinded food 
challenges has rarely been examined.11-13 Using data from single- 
protocol DBPCFCs conducted within the multicenter EuroPrevall birth 
cohort,14-16 we aimed to compare challenge outcomes as defined by 
the experienced and trained study physicians with those based on 
detailed documented signs and symptoms. Our goal was to identify 
areas, which could be improved further to support comparability, in-
cluding techniques used for challenge documentation and interpreta-
tion, and diagnostic algorithms to improve the current gold standard 
for a robust diagnosis of FA.
2  | METHODS
2.1 | Setting and participants
The EuroPrevall birth cohort set out to estimate the frequency and 
factors influencing the onset and duration of FA in 9 study centers in 9 
handling of the protocols. Suspected food allergy was clinically evaluated by double- 
blind, placebo- controlled food challenges using a nine dose escalation protocol. The 
primary challenge outcomes based on physician’s appraisal were compared to docu-
mented signs and symptoms.
Results: Of 839 challenges conducted, study centers confirmed food allergy in 15.6% 
to 53.6% of locally conducted challenges. Centers reported 0 to 16 positive placebo 
challenges. Worsening of eczema was the most common sign when challenged with 
placebo. Agreement between documented objective signs and the challenge outcome 
assigned by the physician was heterogeneous, with Cohen’s kappa spanning from 0.42 
to 0.84.
Conclusions: These differences suggest that the comparison of food challenge out-
comes between centers is difficult despite common protocols and training. We recom-
mend detailed symptom assessment and documentation as well as objective sign- based 
challenge outcome algorithms to assure accuracy and comparability of blinded food 
challenges. Training and supervision of staff conducting food challenges is a mandatory 
component of reliable outcome data.
K E Y W O R D S
data collection, decision-making, diagnostic techniques and procedures, food hypersensitivity, 
observer variation
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different European countries. This initial phase of the cohort ran from 
birth to 30 months of age. Detailed methods have been published pre-
viously.17 In short, 12 049 healthy newborns from the general popula-
tion were enrolled before or shortly after birth and regularly followed 
in 6 month intervals, collecting data including dietary habits and other 
exposures. Parents were instructed to report to their study center im-
mediately upon suspected FA or developing eczema. Additionally, in-
terviews were conducted at 12, 24 and 30 months of age to screen for 
unrecognized signs or symptoms of food allergy. For each child invited 
to the center and two age- matched healthy controls per symptomatic 
child, we performed skin prick tests (SPTs) and measured specific im-
munoglobulin E (sIgE) antibodies in serum against six core allergens 
relevant in childhood (ie, cow’s milk, hen’s egg, wheat, soy, peanut, 
fish), plus suspected other food allergens. The decision to perform 
a DBPCFC was based on a positive test for allergic sensitization (ie, 
SPT wheal ≥3 mm or sIgE ≥0.35 kU/L) without currently eating the 
food, immediate objective clinical signs and symptoms, subjective re-
actions upon repeated exposures or clear improvement under elimina-
tion diet. Food challenges were performed in the participating clinics, 
supervised by trained physicians, and some centers asked families to 
stay overnight. Delayed symptoms were considered up to 48 hours 
after the challenge. Participants with confirmed FA were rechallenged 
after 12 months and, if still eligible, after 24 months of the initial 
diagnosis.
2.2 | Food challenges
The unit of observation for this analysis was a complete challenge in-
cluding one food (verum) and a corresponding placebo control day. A 
single placebo day may have served as a control for more than one 
food in question. Two challenge days were randomly allocated to test 
food or placebo. Challenge and placebo days were at least 48 hours 
apart. Children were fed 9 incremental doses in 20 minute intervals 
under clinical supervision.14 The procedure was stopped at the discre-
tion of the supervising physicians. All physicians were trained in the 
food challenge protocol for this study to harmonize the identification 
of objective signs and symptoms warranting the discontinuation of 
the challenge. However, as food allergy has very diverse appearances, 
it was not possible to formally define all indications for stopping the 
challenge, in particular in light of the patient’s safety. The assessment 
was unblinded after completion of the last challenge day.
In this analysis, we compared three different challenge- based defi-
nitions of food allergy, described in the following paragraphs.
2.3 | Physician’s judgment of challenge outcome
For the first definition (physician’s judgment), study physicians as-
signed outcomes (positive, negative) for each challenge day and then 
concluded an overall judgment after unblinding. This overall con-
clusion was the first definition of food allergy used. Patients were 
judged to be clinically tolerant (both days negative), allergic (test food 
positive, placebo negative), placebo reactors (test food negative, pla-
cebo positive), or inconclusive with regard to food allergy (both days 
positive).
2.4 | Restrictive cutoff for challenge outcome
For the other two definitions of food allergy, clinical observations 
were recorded through a standardized record form with separate 
sections for each challenge step recording immediate and delayed 
(≥2 hours) reactions. Besides skin assessment (SCORAD 18) and vital 
parameters before and after the challenge, 19 specific signs and 
symptoms were collected as dichotomous traits (present or absent). 
Two different cutoff criteria were used to derive sign- and symptom- 
based challenge outcomes. After the judgment of the study physician 
was recorded, the restrictive cutoff (second definition of food allergy) 
to call a challenge positive was derived, limited to immediate urticaria, 
angioedema, flush, emesis, diarrhea, respiratory symptoms, immediate 
or late worsening of eczema with an objective SCORAD increase ≥10, 
and cardiovascular symptoms (never observed in this population).
2.5 | Permissive cutoff for challenge outcome
The permissive cutoff (third definition of food allergy) additionally 
included reactions occurring more than 2 hours after the challenge 
(called delayed) and less pronounced worsening of eczema (SCORAD 
increase of 5 or more).
2.6 | Statistical methods
Calculations were performed using SAS 9.4 (SAS Institute Inc., Cary, 
NC, USA). Missing data was rechecked against the initial study 
F IGURE  1 Hypothetical distribution 
of symptom severity upon double- blind, 
placebo- controlled food challenge in a 
preselected sample of preschool children 
evaluated for suspected food allergy 
matching eligibility criteria (eg, indicative 
history, specific sensitization), stratified by 
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documentation, and only challenges with a known food item and 
study physician’s final outcome decisions (first definition of food 
allergy) were used in this analysis. Agreement between sign- and 
symptom- based (second and third definitions) vs physician’s appraisal 
(first definition, Cohen’s Kappa coefficient 19) was calculated only 
for subsamples large enough to report robust proportion estimates 
(20 + reactive challenges for a single center).
3  | RESULTS
3.1 | Challenge outcomes
A total of 839 valid food challenges (verum- placebo pairs) were 
conducted in the EuroPrevall birth cohort. Although study centers 
were similar in size (976 to 1570 participants), they reported widely 
differing numbers of procedures (7 to 219). Based on study physi-
cian’s judgment (first definition of challenge- based food allergy), 317 
(38.8%) challenges resulted in the diagnosis “allergic” due to a posi-
tive outcome on the verum day and a negative outcome on the pla-
cebo day. Cow’s milk and hen’s egg were the most frequent foods 
in question. Percentages of confirmed FA varied between centers 
(26.1% to 80.0% of conducted challenges). The proportion of allergic 
to challenged children was similar across different ages. Challenges 
with positive placebo day (placebo reactors and inconclusive food 
challenges) were unequally distributed between centers, with a maxi-
mum of 16 procedures in center C. Twenty- eight of all 45 (62.2%) 
challenges with a positive placebo day were related to cow’s milk, with 
a trend toward younger ages (Table 1).
3.2 | Challenge signs and symptoms
A total of 334 of 839 (39.8%) verum (test food) challenge days were 
stopped before starting the final dose, of which most instances were 
judged positive by physicians. Urticaria (30.9%), flush (29.4%), and res-
piratory signs or symptoms (36.8%) were the most frequent reasons 
to stop challenges at lower doses (after step 1 to 4), accompanied by 
subjective gastrointestinal symptoms in 35.3% (not always considered 
as stop criterion on its own, Table 2). Food challenges were commonly 
stopped later (after step 5 to 8) because of urticaria and flush (33.8% 
and 18.4%), usually with no indication of respiratory or subjective gas-
trointestinal symptoms. Emesis and nasal/ophthalmic signs and symp-
toms appeared with increasing dose steps. Worsening of eczema was 
commonly reported (12.0%) but was only considered a stop criterion 
when supported by an objective SCORAD increase≥10. After com-
pleting the final dose (step 9), early (<2 hours) objective skin signs and 
emesis were among the most commonly documented. Delayed reac-
tions (≥2 hours) included diarrhea, subjective gastrointestinal symp-
toms, and often worsening of eczema (without documented SCORAD, 
as parents reported it from home). Of the 101 placebo provocations, 
which did not reach the final dose (both, rated positive or negative), 
no clear sign or symptom was documented to why the procedure was 
stopped. This was likely due to the large amount 14 of test food (both 
for verum and placebo days) relative to children’s age, as reported by 
study personnel. In patients who completed all placebo doses later 
rated as a positive challenge, emesis, diarrhea, flush and worsening of 
eczema were reported after the final placebo dose commonly, both as 
immediate- and delayed- type reactions.
3.3 | Recalculated outcomes based on 
signs and symptoms
All challenge outcomes were later recalculated based on objective 
challenge signs and symptoms. Using criteria as already defined 
within the study protocol (here called restrictive cutoff, second 
definition of food allergy), the number of reactive challenges was 
lower than when based on physician’s judgment (252 vs 317, 22% 
reduction). Comparison of centers revealed pronounced differ-
ences with a reduction of 53% (37 restrictive- diagnosed vs 78 
physician- diagnosed in center C) compared to an increase of 40% 
(21 restrictive- diagnosed vs 15 physician- diagnosed) in center G. 
Including delayed objective signs and a lower SCORAD cutoff (in-
crease ≥5) in the sign- and symptom- based outcome definition (here 
called permissive cutoff, third definition of food allergy), labeled 63 
more challenges reactive, with a maximum in one center of 29 (center 
C, Figure 2). Looking at confirmed FA using a restrictive cutoff, 93 of 
TABLE  1 Outcome of double- blind, placebo- controlled food 







All challenges, n (%) 839 317 (38.8) 45 (5.4)
Country A 139 56 (40.3) 15 (10.8)
B 113 60 (53.1) 9 (8.0)
C 219 78 (35.6) 16 (7.3)
D 75 32 (42.7) 0 (0.0)
E 120 50 (41.7) 3 (2.5)
F 28 15 (53.6) 0 (0.0)
G 96 15 (15.6) 1 (1.0)
H 42 9 (21.4) 0 (0.0)
I 7 2 (28.6) 1 (14.3)
Food Cow’s milk 368 109 (29.6) 28 (7.6)





160 69 (43.1) 6 (3.8)
Other 
allergens
23 6 (26.1) 5 (21.7)
Age 0 - 11 mo 246 100 (40.7) 25 (10.2)
12 - 23 mo 369 131 (35.5) 12 (3.3)
24 mo and 
older
224 86 (38.4) 8 (3.6)
awith or without a positive verum day.
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252 (36.9%) challenges did complete all steps of the placebo day as 
would have been required by the study protocol. This occurred simi-
larly at all ages. Centers varied with respect to not finishing placebo 
challenges (descending frequencies, center G 57.1, C 56.8, E 51.2%). 
The two cutoffs resulted in different numbers of reactive challenges 
across all ages (Figure S1).
3.4 | Sign- and symptom- based outcomes vs 
physician’s appraisal
The agreement between sign- and symptom- based challenge day 
outcomes using the restrictive cutoff (considered as stopping criteria 
in the study protocol) and physician’s judgment/diagnosis varied be-
tween study centers, with the lowest agreement in center C yielding a 
Cohen’s kappa coefficient of 0.42, and highest agreement in center D 
(kappa 0.84). Higher degrees of agreement were achieved using 
permissive cutoff criteria, which were more similar between centers 
(range center C 0.74 to D 0.92, Figure 3).
4  | DISCUSSION
4.1 | Main results
There were differences between centers comparing physician’s ap-
praisal and sign- and symptom- based outcomes recorded during 
blinded food challenges of infants and young children up to the age 
of 2 years within the multicenter EuroPrevall birth cohort study. The 
agreement between the permissive cutoff and physician’s appraisal 
was higher compared to the restrictive criteria, indicating a tendency 
for study physicians to apply a rather permissive decision threshold.
Dose- symptom interval 
highest dose administeredb
Verum day Placebo day
<2 h ≥2 h <2 h ≥2 h
1.4 5.8 9 1.9 1.4 5.8 9 1.9
Number of challenges (68) (266) (505) (839) (22) (79) (551) (652)
Skin
Urticaria 21 90 28 26 6 2 0 2
Angioedema 5 11 3 5 0 0 0 0
Flush 20 49 26 29 0 2 7 4
Eczema
Any 7 32 27 81 2 1 11 18
Increased SCORAD ≥5 2 17 9 11 1 1 0 0
Increased SCORAD 
≥10
1 10 5 2 1 0 0 0
Gastrointestinal
Emesis 9 33 21 23 0 2 9 4
Diarrhea 1 7 6 41 0 1 1 6
Subjective (pain, nausea, 
OAS)
24 0 0 27 3 0 0 3
Respiratory, ENT
Airwaysa 25 0 0 1 0 0 0 1
Nasal 3 15 5 5 0 0 0 0
Ophthalmic 1 14 5 6 0 0 0 0
OAS, oral allergy syndrome; ENT, Earnose and throat.
aFollowing a nine dose protocol as explained in(14).
bBronchospasm, dyspnea, cough, laryngoedema.
TABLE  2 Symptoms following highest 
administered dose, by challenge day 
(verum/placebo). All centers, all ages, all 
food items. Numbers represent single 
challenge days. Shading: symptoms 
accounted for as stop criteria used in 
symptom- based challenge outcome 
definition (light: permissive cutoff, dark: 
restrictive cutoff). The following symptoms 
were never reported and thus not shown 
here: Blisters in oral mucosa, dysphagia, 
blood pressure drop, and shock
F IGURE  2 Number of reactive challenges per study center (of 9), 
based on symptom profile. Permissive cutoff including delayed 
reactions and worsening of eczema with a SCORAD increase ≥5, 
restrictive cutoff accounting only for early objective symptoms and 
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The wide range of positive challenge outcomes between centers 
(15.6% to 53.6%) might either be due to a real difference in disease 
incidence, unequal inclusion thresholds to perform a challenge testing, 
or may, at least in part, result from differences in documenting and 
interpreting signs and symptoms of oral food challenges. This empha-
sizes the need for standardization of all aspects of DBPCFCs including 
inclusion criteria, documentation of denial to participate, challenge 
conduct, and interpretation of the challenge outcome.
While the necessity of blinding in food challenges has been ques-
tioned (eg, 20), the considerable numbers of signs and symptoms during 
placebo challenges seen in this study, especially delayed self- reported 
eczema (18 times on placebo vs 81 on test food days), demonstrate 
that blinding is imperative for accurate interpretation of food chal-
lenges. Interestingly, subjective gastrointestinal symptoms occurred 
almost only during the first lower doses, whereas subjective ENT 
symptoms and worsening of eczema were more common with higher 
doses of the tested allergen. This could be due to different mecha-
nisms of action, be it psychologic or biologic. The frequent failure to 
reach the final dose during placebo challenges might be explained by 
the relatively large amounts of challenge agent used. Interestingly, a 
high number of placebo reactors were seen in the first year of life, as 
has been shown previously.21 This finding stresses the need to per-
form blinded food challenges even in very young patients.
Detailed assessment and documentation of challenge signs and 
symptoms is a cornerstone of comparability, as seen by the difference 
between any eczema and SCORAD- scored eczema at the highest dose 
administered (on 66 vs 16 test food days). It is likely that grading of 
other signs and symptoms could further improve the accuracy of food 
challenges. Additionally, only three centers (A, C, F) recorded consid-
erable numbers of subjective symptoms, supporting the need for a de-
tailed assessment and documentation of these observations to be part 
of the challenge protocol. These details could include grading, mea-
surement, or weighting to improve comparability of challenge results.
That judgment of symptoms and clinical signs always relies on indi-
vidual experience and appraisal threatens the validity of comparisons 
between study centers and observers, indicated by the considerable 
differences of positive placebo challenges (0 to 16 per center) and vari-
able agreement comparing physician- based vs objective sign- based 
challenge outcomes (Cohen’s kappa spanning from 0.42 to 0.84, re-
strictive cutoff). In general, using a permissive cutoff yielded higher 
agreement with physician- based outcomes in all centers, highlighting 
the need for a unified, robust, and objective sign- based case definition 
for research.
4.2 | Recommendations
Development and standardization of current guidelines and challenge 
protocols 4,8 for the diagnosis of FA in the clinical setting are ongo-
ing and should be promoted.1,2,5 Their focus lies mainly on methodo-
logical aspects in light of their first priority, to rule out or confirm FA 
in real- life medical care settings. Consequently, looking at different 
steps from suspicion to confirmation of FA, blinding of challenges, 
detailed sign and symptom assessment, and standardized interpreta-
tion of challenge outcomes are usually neglected,3,22 relying mainly on 
personal experience and individual judgment (Figure 4). When food 
challenges are used in research settings, these procedural aspects 
are likely to influence estimates of disease frequency and severity 
considerably and must not be ignored in study protocols. Here, com-
parability and restrictive case definitions outweigh the usual “don’t- 
miss- any” approach, which is appropriate for individual care, where a 
false positive is a safer misclassification than a false negative.
As was done in this study, preparation and distribution of test food 
and placebo substrate should be centralized and off- site in research 
settings, ensuring a high degree of blinding. Unblinding must be de-
layed until after the challenge documentation has been closed and, as 
is suggested to assess allocation concealment in clinical trials, blinding 
success should be documented by assessing participant’s and study 
personnel’s guessed allocation of each of the challenge days.
Secondly, already proposed but usually not implemented,5 all 
signs and symptoms should be quantified using appropriate mea-
sures such as size, distribution, and severity for skin manifestations 
beyond eczema, or amount and kind of vomit and diarrhea. Moreover, 
F IGURE  3 Agreement between 
study physician’s judgment and symptom 
profile, using different symptom cutoffs 
(restrictive, permissive). Comparison 
of single day outcomes (test food and 
placebo). Asymptotic 95% confidence 
intervals, 4 of 9 study centers omitted due 
to low numbers of challenges
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there is an urgent need for a standardized assessment of potentially 
relevant gastrointestinal symptoms like colic, and general symptoms 
like crying and being uncomfortable. This is particularly needed for 
signs and symptoms commonly reported during placebo challenges 
and as delayed reactions (flush, urticaria, GI symptoms, 23). Variation 
of clinical signs and symptoms, for example, worsening of eczema 
during or after the challenge day, can ideally be assessed by two in-
dependent physicians, the second blinded to judgment of the first, 
and not by parents alone. Peer- to- peer teaching and training of re-
action assessment may shed light on under- or over- recognized signs 
and symptoms and improve comparability. As aimed for in this study, 
data entry for each challenge day should be closed before starting 
the next day. Additionally, documentation of challenge details would 
support any independent and objective consideration of challenge 
outcomes. These might include intentional and feasible protocol vi-
olations (eg, omission of the final dose), information about medical 
personnel (eg, level of experience), and the post- challenge period (eg, 
re- introduction of food, exact timing, and assessment of delayed re-
actions through professionals).
Thirdly, after closing data entry, a centralized evaluation scheme 
could assign the final challenge outcome based on recorded signs and 
symptoms, with the need to register its technical implementation as 
a medical device. Personnel on site should be asked to label observa-
tions they suspect to be causally linked to the ingested food, be it the 
allergen or placebo. Challenge outcome and day allocation (unblinding) 
could then be finally returned to the clinical site.
Finally, using a generic online platform for research as well as in-
dividual care settings may facilitate data entry, for example, ensuring 
that data entry for each challenge day was closed before starting the 
next day, and allowing on- time queries and electronic evaluation of 
challenge outcomes. Such an algorithm could be asked to return a bi-
nary decision (tolerant/reactive) using a rather loose cutoff with the 
intent to not miss any FA. It may at the same time report quantified 
severity of the reaction using other cutoffs, ultimately improving com-
parability between physicians, clinical sites, and countries.
Improving challenge guidelines is recommended to incorporate 
what we have demonstrated in this single- protocol, multicenter proj-
ect, which could also be expected to be beneficial for regular patient 
care and other research settings.
4.3 | Strengths and limitations
As the current gold standard, blinded food challenges cannot be cali-
brated against another diagnostic test. Therefore, we used the ideal 
setting of a large single- protocol, multicenter research project to 
indirectly identify potential shortcomings of its diagnostic capabilities. 
Given stability of study personnel over time, heterogeneity of study 
centers in terms of initial experience with food challenges and dif-
ferent societal backgrounds between centers has allowed us to as-
sess the influence of subjective (often undefined or not accessible) 
parameters, but we had no estimates for the individual experience of 
participating physicians. With the lack of comparable prior knowledge 
about disease frequency and distribution of potential subtypes of FA 
in participating countries, we were not able to directly separate true 
from factitious intercenter differences. We cannot prove that these 
differences indicate the influence of subjective parameters within this 
project alone or are rather due to possible disease heterogeneity, but 
with the procedural aspects identified here accounted for in future 
research, we will be closer to a true gold standard. Of note, the study 
was neither designed nor powered for the presented analyses.
4.4 | Conclusion
There is no methodology to assess the accuracy and other diagnostic 
characteristics of blinded food challenges directly. We demonstrated 
differences between centers of the multicenter EuroPrevall project in 
terms of overall reactivity to challenges, placebo reactions, and most 
importantly decision thresholds for assigning challenge outcomes 
based on physician’s judgment. Despite using the same robust, high-
est standard challenge protocol, these discrepancies suggest there can 
still be a residual influence of subjective and other non- standardized 
parameters, threatening valid comparison of results between centers, 
if challenge outcome is not based on objective signs.
We recommend centralized provision of allergens for food chal-
lenges, implementation of detailed sign and symptom quantification, 
and timely documentation in standardized challenge record forms and 
that only pre- agreed sign- and symptom- based challenge outcomes 
derived by unified algorithms should be relied upon. These allow for 
continuous severity grading in addition to the usual dichotomous 
challenge outcome and provide valuable information for inter- and 
within- study comparisons. The school- age follow- up (iFAAM) of the 
EuroPrevall project implemented these recommendations using case 
report forms that are publicly available (CRFs, 24). Accounting for these 
recommendations will further improve the diagnostic gold standard of 
blinded food challenges for food allergies.
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F IGURE  4 Blinded food challenge 
methodology. Highlighted aspects are 
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